Riad Salem, MD, MBA

Expert panelists consider later-line treatment options for a patient with recurrent hepatocellular carcinoma.

Comprehensive insight on several clinical trials analyzing frontline combination therapies for patients with unresectable hepatocellular carcinoma.

In the setting of unresectable hepatocellular carcinoma, experts consider the role of frontline atezolizumab + bevacizumab given data from IMbrave150.

A brief review of treatment options for patients with Child-Pugh B grade metastatic hepatocellular carcinoma.

Panelists consider the adverse event profile of frontline TKI therapy in patients with metastatic HCC and review options for dosing and dose reduction.

Comprehensive discussion on the PFS subgroup data from REFLECT, which compared frontline lenvatinib and sorafenib therapy in metastatic HCC.

Shared insight on clinical trial data in metastatic hepatocellular carcinoma supporting frontline use of sorafenib and lenvatinib, respectively.

Focused discussion on the frontline treatment options available for patients diagnosed with metastatic hepatocellular carcinoma.

Panelists debate the role of imaging in conjunction with or in place of biopsy in the setting of metastatic hepatocellular carcinoma.

Shifting to a second patient case of metastatic hepatocellular carcinoma, experts consider best diagnostic practices and the initiation of therapy.

A brief discussion on the role of systemic therapies in combination with or following TACE/TARE in unresectable hepatocellular carcinoma.

Expert perspectives on the role of transarterial radioembolization in unresectable hepatocellular carcinoma following FDA approval.

Sharing the first patient case of unresectable hepatocellular carcinoma, experts consider optimal screening and diagnosis practices in this setting.